Harmony Biosciences Holdings, Inc. (HRMY) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Harmony Biosciences Holdings, Inc.

Madrigal Pharmaceuticals, Inc.

Prestige Consumer Healthcare, Inc.

Corcept Therapeutics, Inc.

Cytokinetics, Inc.

Xenon Pharmaceuticals, Inc.

Ultragenyx Pharmaceutical, Inc.

Amphastar Pharmaceuticals, Inc.

Akero Therapeutics, Inc.

MoonLake Immunotherapeutics

Bausch Health Cos., Inc.

Why is Harmony Biosciences Holdings, Inc. ?

High Management Efficiency with a high ROE of 27.07%

Company has a low Debt to Equity ratio (avg) at times

Healthy long term growth as Net Sales has grown by an annual rate of 67.93% and Operating profit at 36.01%

Positive results in Jun 25

OPERATING CASH FLOW(Y) Highest at USD 259.38 MM
NET PROFIT(Q) At USD 39.78 MM has Grown at 243.16%
PRE-TAX PROFIT(Q) At USD 49.64 MM has Grown at 128.81%

With ROE of 21.20%, it has a attractive valuation with a 2.84 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 1.82%, its profits have risen by 5.4% ; the PEG ratio of the company is 3.1

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Harmony Biosciences Holdings, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Harmony Biosciences Holdings, Inc. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Harmony Biosciences Holdings, Inc.

10.87%

0.43

42.08%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

67.93%

EBIT Growth (5y)

36.01%

EBIT to Interest (avg)

6.67

Debt to EBITDA (avg)

0.20

Net Debt to Equity (avg)

-0.42

Sales to Capital Employed (avg)

0.81

Tax Ratio

22.55%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

45.85%

ROE (avg)

27.07%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.84

EV to EBIT

8.94

EV to EBITDA

7.96

EV to Capital Employed

4.15

EV to Sales

2.34

PEG Ratio

3.11

Dividend Yield

ROCE (Latest)

46.44%

ROE (Latest)

21.20%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

17What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 259.38 MM

NET PROFIT(Q)

At USD 39.78 MM has Grown at 243.16%

PRE-TAX PROFIT(Q)

At USD 49.64 MM has Grown at 128.81%

RAW MATERIAL COST(Y)

Fallen by -0.06% (YoY

CASH AND EQV(HY)

Highest at USD 1,072.23 MM

DEBT-EQUITY RATIO (HY)

Lowest at -46.06 %

INVENTORY TURNOVER RATIO(HY)

Highest at 32.56 times

-1What is not working for the Company

DEBTORS TURNOVER RATIO(HY)

Lowest at 8.77 times

Here's what is working for Harmony Biosciences Holdings, Inc.

Net Profit

At USD 39.78 MM has Grown at 243.16%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Operating Cash Flow

Highest at USD 259.38 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit

At USD 49.64 MM has Grown at 128.81%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Cash and Eqv

Highest at USD 1,072.23 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -46.06 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio

Highest at 32.56 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -0.06% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Harmony Biosciences Holdings, Inc.

Debtors Turnover Ratio

Lowest at 8.77 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio